Navamedic

Navamedic ASA: Navamedic has entered into an agreement in principle with Observe Medical ASA to reduce the loan receivable by 50%

Oslo, April 10 2025. Navamedic ASA (OSE ticker "NAVA") has entered into an

agreement in principle regarding the outstanding loans to Observe Medical ASA.

The agreement reduces the loans by 50% with an adjustment to the payment plan as

long as certain conditions are met, including the injection of new equity in

Observe Medical ASA from other parties of at least 25MNOK, and that other

creditors also reduces their debt at the same level. Navamedic will further have

the possibility of receiving milestone payments up to 20MNOK based on Observe

Medical ASA achieving certain sales levels of Sippi.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation and is subject to the disclosure requirements pursuant

to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lars Hjarrand, CFO of the

Company, on 10 April 2025 at 08.50 hours CET on behalf of the Company.

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to

empower people to live healthier and more fulfilling lives. What sets us apart

is our deep-rooted commitment to understanding the needs and requirements of the

countries where we are present. Our local insight and competence enable us to

understand the specific needs of each country where we operate and ultimately to

gain market access. This makes us a preferred partner for international

companies expanding their footprint across the Nordics and Benelux regions,

through either in-licensing or out-licensing. Navamedic has been listed on the

Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,

Norway. For more information, please visit Navamedic.com.

AI Terminal